Article
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
The pharmacogenomics journal - 1 Oct 2013
Ji Y, Biernacka J M, Hebbring S, Chai Y, Jenkins G D, Batzler A, Snyder K A, Drews M S, Desta Z, Flockhart D, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Schaid D, Weinshilboum R M, Mrazek D A
Abstract excerpt
A genome-wide association (GWA) study of treatment outcomes (response and remission) of selective serotonin reuptake inhibitors (SSRIs) was conducted using 529 subjects with major depressive disorder. While no SNP associations reached the genome-wide level of significance, 14 SNPs of interest were identified for functional analysis. The rs11144870 SNP in the riboflavin kinase (RFK) gene on chromosome 9 was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.